Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Consulting agrmnt
Director departure
Quarterly results
Appointed director
CC transcript
Inv. presentation
MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/25/2019 8-K Bankruptcy or Receivership, Financial Statements and Exhibits
01/04/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MabVax Therapeutics and Oncotelic Enter into Merger Discussions Divestiture of Selected MabVax Assets Managed by Objective Capital Will Continue SAN DIEGO – MabVax Therapeutics Holdings, Inc. , a clinical-stage immuno-oncology drug development company with a fully human antibody discovery platform focused on the clinical development of products to address unmet medical needs in the treatment of cancer and pancreatitis, today announced that it has entered into discussions to merge with Oncotelic, Inc., a privately held cancer immunotherapy company. Oncotelic is developing a unique TGF- antisense therapy which has demonstrated the ability to break immune tolerance in mid-stage clinical trials for the treatment of glioblastoma and pancreatic cancer. Based on terms of a non-binding letter of i..."
11/20/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Equity Purchase Agreement with Triton Funds LP",
"Registration Rights Agreement",
"Share Donation Agreement"
10/16/2018 8-K Quarterly results
07/09/2018 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MabVax Therapeutics and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers"
07/05/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "MabVax Therapeutics Receives Nasdaq Delist Determination San Diego, CA, July 5, 2018 – MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that as a result of the Company’s decision not to submit a plan to regain compliance with Nasdaq’s filing requirement, which decision was announced by the Company in a press release on July 2, 2018, on that same date, the Listing Qualifications Staff of The Nasdaq Stock Market LLC notified the Company of its determination to delist the Company’s securities from Nasdaq. The Staff indicated that the determination was based upon the Company’s non-compliance wi..."
07/03/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "ADDITIONAL EXHIBITS"
07/02/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "MabVax Therapeutics Decides Not to Submit Plan to Regain Compliance with Nasdaq Listing Standards"
05/24/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "MabVax Therapeutics Receives Nasdaq Notification Due to Late Form 10-Q"
05/22/2018 8-K/A Financial Statements and Exhibits
Docs: "Letter from CohnReznick LLP to the Securities and Exchange Commission"
05/21/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previous...
05/03/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
Docs: "Certificate of Designations, Preferences and Rights of the 0% Series N Convertible Preferred Stock",
"Certificate of Correction to Certificate of Designations, Preferences and Rights of the 0% Series N Convertible Preferred Stock",
"Certificate of Designations, Preferences and Rights of the 0% Series O Convertible Preferred Stock",
"Form of Purchase Agreement",
"Form of Registration Rights Agreement",
"Form of May 2018 Letter Agreement",
"MabVax Therapeutics Holdings, Inc. Announces Private Placement Offering SAN DIEGO, May 3, 2018 – MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced it has entered into securities purchase agreements with accredited investors pursuant to which the Company has agreed to sell $860,000 worth of shares of the Company’s newly designated 0% Series N Convertible Preferred Stock . Transaction costs are estimated to be $10,000. The initial conversion price for the Series N Preferred Stock is $1.10 per share of common stock. The offering is expected to close on or before May 7, 2018. In connection with this offering, the Company offered incentive sh..."
05/03/2018 8-K Investor presentation
Docs: "Power Point Presentation"
04/18/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "ADDITIONAL EXHIBITS"
04/13/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "MabVax Therapeutics Receives Continued Listing Deficiency Notice for Nasdaq’s Minimum Stockholders’ Equity Requirements - No immediate effect on the Company's Nasdaq listing or the trading of its common stock -"
04/02/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MabVax Therapeutics Reports 2017 Operational and Financial Results and 2018 Milestones – 2017 marked by clinical advancement of treatments for various cancers - – Management on track to execute value-driving corporate and clinical milestones in the first half of 2018 – – Company expects to complete one or more strategic transactions with third parties that are intended to unlock significant value in 2018 –"
03/06/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MabVax Therapeutics Regains Compliance with NASDAQ’s $1.00 Minimum Bid Price Maintenance Requirement SAN DIEGO, March 6, 2018 – MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that it received a letter from the Listing Qualifications Department of The NASDAQ Capital Market notifying the Company that it has regained compliance with Nasdaq Listing Rule 5550 as a result of maintaining the $1.00 minimum closing bid price for at least ten trading days prior to the March 5, 2018 deadline for continued listing. The Company regained compliance with the minimum bid price maintenance requirement as a result of completing on February 16, 2018 its..."
02/28/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers – Safety results in first cohort enable patient enrollment in second cohort at increased dose – – Tumor target specificity and accumulation of radiolabeled antibody demonstrated in first cohort of treated patients – SAN DIEGO, February 28, 2018 – MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today positive interim results from the initial cohort of the Phase 1 clinical trial evaluating the Company’s new human antibody-based radioimmunotherapy product MVT-1075 for the tr..."
02/15/2018 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MABVAX THERAPEUTICS HOLDINGS, INC. MabVax Therapeutics Holdings, Inc. , a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: FIRST: The name of the Corporation is MabVax Therapeutics Holdings, Inc. The date of filing of the Corporation’s original Certificate of Incorporation with the Secretary of State of the State of Delaware was October 20, 1988. SECOND: The Board of Directors of the Corporation duly adopted resolutions setting forth proposed amendments to the Corporation’s Amended and Restated Certificate of Incorporation, as amended , declaring said amendments to be advisable and directing that said amendments be submitted to the ...",
"MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ’s $1.00 Minimum Bid Price Maintenance Requirement San Diego, CA, February 15, 2018 -- MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that the Board of Director’s previously approved 1-for-3 reverse stock split is scheduled to be effective with the opening of trading on the NASDAQ Capital Markets on Friday, February 16, 2018 on a split-adjusted basis under the trading symbol “MBVX.” The primary intent of the reverse split is to increase the market price of the Company’s common stock in order to regain compliance..."
02/12/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
02/12/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer ● All treated patients had measurable tumor reductions ● Promising early results merit additional enrollment ● Company aiming to establish the potential of combination of MVT-5873 with first line therapy in pancreatic cancer SAN DIEGO, February 12, 2018 – MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today positive interim results from the Company’s ongoing Phase 1 trial evaluating MVT-5873 in combination with standard of care chemotherapy in pati..."
02/12/2018 8-K Investor presentation
Docs: "Power Point Presentation dated February 2018"
02/06/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation ...
01/30/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MabVax Receives Notice of SEC Investigation and Examination of Certain Registration Statements San Diego, January 30, 2018 -- MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that it received notice that the Securities and Exchange Commission was conducting an investigation and examination pursuant to Section 8 of the Securities Act of 1933, as amended, relating to certain of the Company’s registration statements . The Company intends to cooperate fully with the SEC’s examination. About MabVax MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid ..."
01/16/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update – Company makes solid progress in advancing discussions with multiple third parties in the evaluation of strategic options that are expected to unlock significant value – – Management on track to execute value-driving corporate and clinical milestones in the first half of 2018 – SAN DIEGO, January 16, 2018 – MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today provided an update on its business strategy initiatives. In September 2017, MabVax announced its engagement with Greenhill & Co. to serve as an advisor to assist the Company in exploring and evaluating strategic options with t..."
12/21/2017 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Certificate of Elimination of Series F, Series G, and Series H Preferred Stock"
12/20/2017 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy – Company plans to announce interim safety and RECIST data Q1 2018 – SAN DIEGO, December 20, 2017 – MabVax Therapeutics Holdings, Inc. , a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today the completion of enrollment and initial patient dosing in an expanded cohort of the Company’s Phase 1 trial evaluating MVT-5873 in combination with standard of care chemotherapy in newly diagnosed patients with pancreatic and other CA19-9 positive malignancies. In October, the Company provided an update ..."
12/13/2017 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MabVax Therapeutics Announces Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers"
12/01/2017 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "MabVax Stockholders Approve Proposals at Special Meeting of Stockholders San Diego, December 1, 2017 -- MabVax Therapeutics Holdings, Inc. a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that its stockholders approved all proposals at a Special Meeting of Stockholders re-convened on December 1, 2017 , after achieving a quorum on the proposals to be approved. The following proposals were voted upon and approved by the stockholders on December 1, 2017: 1. To approve the potential issuance of up to an aggregate of 9,666,667 shares of common stock, in excess of 19.99% of the number of shares of common stock that were issued and outstanding on October 17, 2017, upon the conver..."
11/22/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "MabVax Announces Adjournment of Special Meeting of Stockholders Special Meeting to Resume on Friday, December 1, 2017 San Diego, November 22, 2017 -- MabVax Therapeutics Holdings, Inc. a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that its Special Meeting of Stockholders scheduled for and convened on November 22, 2017 , was adjourned to achieve a quorum on the proposals to be approved. The Special Meeting has been adjourned to 11:00 a.m. Pacific Standard Time/2:00 p.m. Eastern Standard Time on Friday, December 1, 2017, at the offices of the Company at 11535 Sorrento Valley Road, Suite 400, San Diego, CA 92121, to allow additional time for MabVax stockholders to vote on ..."
11/16/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "MabVax Therapeutics Regains Compliance with Nasdaq’s Minimum Stockholders’ Equity Listing Requirements SAN DIEGO – MabVax Therapeutics Holdings, Inc. , a clinical-stage oncology drug development company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, today announced that it received a letter from the Listing Qualifications Department of the NASDAQ Capital Market notifying the Company that it has regained compliance with the Nasdaq Listing Rule requiring companies to maintain a minimum of $2,500,000 in stockholders' equity for continued listing as of September 30, 2017. The Company regained compliance with the stockholders’ equity requirement as a result of the completion of successful financings totaling $4.75 million during ..."
10/19/2017 8-K Quarterly results
10/11/2017 8-K Quarterly results
10/11/2017 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy